Showing results (361-370 of 387) with videos related to

Sort By:
Pageof 39
Journal of Parkinson'S Disease|March 8, 2021
Parkinson's Disease Subtypes: Critical Appraisal and RecommendationsTiago A Mestre, Seyed-Mohammad Fereshtehnejad, Daniela Berg, et al.
Neurology|February 2, 2024
Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
The Lancet. Neurology|December 17, 2016
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysisDavid J Irwin, Murray Grossman, Daniel Weintraub, et al.
NPJ Parkinson'S Disease|May 3, 2024
Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide levelThomas F Tropea, Whitney Hartstone, Noor Amari, et al.
Neurology|August 7, 2024
Long-Term Dementia Risk in Parkinson DiseaseJulia Gallagher, Caroline Gochanour, Chelsea Caspell-Garcia, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
JAMA Neurology|September 3, 2014
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson diseaseIgnacio F Mata, James B Leverenz, Daniel Weintraub, et al.
Brain : a Journal of Neurology|June 8, 2018
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associatedJohn L Robinson, Edward B Lee, Sharon X Xie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2023
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsStefanie T Jost, Marie-Ann Kaldenbach, Angelo Antonini, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
Pageof 39